Related Experiment Videos
Cyclooxygenases and colon cancer
Naoki Kawai1, Masahiko Tsujii, Shingo Tsuji
1Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan.
Prostaglandins & Other Lipid Mediators
|November 16, 2002
Summary
Cyclooxygenase-2 (COX-2) plays a key role in colon cancer development and progression. Inhibiting COX-2 with drugs like NSAIDs shows promise for colon cancer prevention and treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cyclooxygenase-2 (COX-2) is implicated in colon carcinogenesis.
- Nonsteroidal anti-inflammatory drugs (NSAIDs), which target COX-2, reduce colon cancer mortality.
- Elevated COX-2 mRNA and protein levels are observed in colon cancer tissues and cell lines.
Purpose of the Study:
- To investigate the role of COX-2 in colon cancer.
- To explore the therapeutic potential of COX-2 inhibitors in colon cancer.
Main Methods:
- Analysis of COX-2 expression in patient tissues and cell lines.
- Studies using murine models of adenomatous polyposis coli.
- Evaluation of NSAIDs and gene knockouts in reducing intestinal polyps.
- Assessment of COX-2's role in apoptosis, angiogenesis, invasion, and metastasis.
Main Results:
- COX-2 expression in intestinal epithelial cells promotes apoptosis resistance, angiogenesis, invasion, and metastasis.
- COX-2 in stromal cells contributes to tumor angiogenesis.
- NSAIDs and COX-2 gene knockouts reduce intestinal polyp formation in mice.
- NSAIDs demonstrate both COX-2 dependent and independent effects on colon cancer growth.
Conclusions:
- COX-2 is a significant factor in colon cancer progression.
- Targeting COX-2 with selective inhibitors offers a promising strategy for colon cancer prevention and treatment.